This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
QIAGEN (QGEN) Digital COVID-19 Antibody Test Gets FDA's EUA
by Zacks Equity Research
QIAGEN's (QGEN) QIAreach Anti-SARS-CoV-2 test takes nearly 10 minutes to detect whether a person carries antibodies to the SARS-CoV-2 virus as a result of prior infection.
LabCorp (LH) Base Line Growth Solid, COVID-Related Sales Drop
by Zacks Equity Research
LabCorp's (LH) Walgreens-partnership expands to include new integrated digital experiences.
4 Medical Products Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Rebound in base sales make us optimistic about OMI, INGN, XRAY and CNTG's results this time around.
LabCorp (LH) Q1 Earnings Surpass Estimates, View Raised
by Zacks Equity Research
LabCorp's (LH) raises 2021 guidance but projects significant sinking of COVID-related testing revenues.
LabCorp (LH) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
LabCorp (LH) delivered earnings and revenue surprises of 20.08% and 7.39%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Medical Products' Apr 29 Earnings Roster: TMO, BAX & More
by Trina Mukherjee
The Medical Product companies' first-quarter results are likely to reflect robust earnings and revenue growth on solid base business recovery.
Why Earnings Season Could Be Great for LabCorp (LH)
by Zacks Equity Research
LabCorp (LH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
LabCorp (LH) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
With respect to LabCorp's (LH) COVID-19 testing services wing, although extensive vaccine rollouts are ongoing, the resurgence of the virus might have once again boosted testing demand in Q1.
LabCorp (LH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
LabCorp (LH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why LabCorp (LH) Could Beat Earnings Estimates Again
by Zacks Equity Research
LabCorp (LH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why You Should Hold on to LabCorp (LH) Stock Now
by Zacks Equity Research
Investors are optimistic about LabCorp (LH) backed by its strong diagnostic arm growth and progress in Covance business.
Myriad Genetics' (MYGN) myChoice Gets Additional Reimbursement
by Zacks Equity Research
Myriad Genetics' (MYGN) myChoice test's additional reimbursement will now make it available for use in first-line treatment of advanced ovarian cancer patients.
Thermo Fisher (TMO) Launches Surveillance Tool for COVID-19
by Zacks Equity Research
The latest launch of surveillance solution is an extremely timely development by Thermo Fisher (TMO) and is expected to witness fast market adoption.
LabCorp (LH) Banks on Structural Review Plan for Solid Returns
by Zacks Equity Research
LabCorp (LH) plays a critical role in terms of COVID-19-related developments as well as makes progress in other key therapeutic areas.
5 MedTech Growth Stocks Gaining Ground in 2021 Amid Pandemic
by Debanjana Dey
Here are a few MedTech stocks, ABT, HOLX, HRC, IDXX, LMAT, which have held their ground amid the pandemic and can turn out to be wise investment choices for 2021.
LabCorp (LH) Moves 4.9% Higher: Will This Strength Last?
by Zacks Equity Research
LabCorp (LH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
The Zacks Analyst Blog Highlights: Quest Diagnostics, LabCorp, InMode, Bioanalytical Systems and Semler Scientific
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Quest Diagnostics, LabCorp, InMode, Bioanalytical Systems and Semler Scientific
Fed Eyes Faster Recovery in 2021: 3 MedTech Stocks to Buy
by Urmimala Biswas
MedTech stocks like INMD, BASI and SMLR are expected to maintain market-beating momentum in 2021.
3 Stocks to Capitalize on Promising Dental Supplies Industry
by Trina Mukherjee
Despite the challenges thrown by the COVID-19 pandemic, teledentistry coupled with AI & Robotics should lend support to the Zacks Medical - Dental Supplies industry. MCK, WST and CAH are well-poised to gain from the prospects.
Pacific Biosciences' (PACB) Sequel II Gets Deployed by LabCorp
by Zacks Equity Research
Pacific Biosciences' (PACB) Sequel II HiFi sequencing gets utilized by LabCorp to detect SARS-COV-2 variants in the United States.
4 Medical Products Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Rebound in sales volumes and rise in COVID-19 support products sales make us optimistic about MDT, MASI, XRAY and COO's results.
LabCorp's (LH) New Antigen Test to Spot Active COVID-19 Virus
by Zacks Equity Research
LabCorp's (LH) new antigen test is the newest development to detect COVID-19 infection at every single stage, from diagnostic testing to vaccination trails.
LabCorp (LH) Q4 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
LabCorp's (LH) 2021 guidance projects significant downfall in COVID-related testing revenues.
LabCorp (LH) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
LabCorp (LH) delivered earnings and revenue surprises of 31.18% and 12.94%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Medical Products' Feb 11 Earnings Roster: DXCM, LH & More
by Trina Mukherjee
The Medical Product companies' fourth-quarter results are likely to reflect huge adoption of COVID-19 related healthcare-support products and services despite the impact of the ongoing pandemic.